China’s First Insulin Tender Hits Multinationals Hard

An average overall price reduction of 48% for insulin products in China is expected to generate annual savings of $1.4bn through 2023, but multinational pharma firms will be hit hard by the bidding process.

Multi-nationals are set to lose market share in insulin to Chinese competitors in China.
Multinationals set to lose insulin market share to local competitors in China • Source: Alamy

Multinational pharma firms Novo Nordisk A/S, Sanofi and Eli Lilly and Company have been hit hard in China’s first volume-based tender program for insulin products, amid deep slashes in prices and tender volumes, according to a report published by Chinese brokerage firm CITIC Securities on 29 November.

On 26 November, the three companies, along with eight Chinese domestic insulin makers, participated in a tender program organized by...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia